S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
This Is A Memorable Time To Buy Into Micron Technology
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
NATO chief rejects Russia’s “illegal and illegitimate” annexation of 4 parts of Ukraine
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
This Is A Memorable Time To Buy Into Micron Technology
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
NATO chief rejects Russia’s “illegal and illegitimate” annexation of 4 parts of Ukraine
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
This Is A Memorable Time To Buy Into Micron Technology
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
NATO chief rejects Russia’s “illegal and illegitimate” annexation of 4 parts of Ukraine
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
This Is A Memorable Time To Buy Into Micron Technology
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
NATO chief rejects Russia’s “illegal and illegitimate” annexation of 4 parts of Ukraine
West rejects Putin's claim it sabotaged Baltic gas pipelines
NASDAQ:APDN

Applied DNA Sciences - APDN Stock Forecast, Price & News

$1.13
-0.09 (-7.38%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.12
$1.35
50-Day Range
$0.68
$5.83
52-Week Range
$0.62
$7.35
Volume
347,930 shs
Average Volume
2.61 million shs
Market Capitalization
$13.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Applied DNA Sciences MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
519.5% Upside
$7.00 Price Target
Short Interest
Healthy
6.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of Applied DNA Sciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.43) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Industrial Products Sector

171st out of 187 stocks

Miscellaneous Business Services Industry

6th out of 6 stocks

APDN stock logo

About Applied DNA Sciences (NASDAQ:APDN) Stock

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Receive APDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied DNA Sciences and its competitors with MarketBeat's FREE daily newsletter.

APDN Stock News Headlines

APDN Applied DNA Sciences, Inc.
Applied DNA Sciences (NASDAQ:APDN) Upgraded to Hold by StockNews.com
Applied DNA Sciences, Inc. (APDN)
Applied DNA Launches Monkeypox Testing Service
See More Headlines
Receive APDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied DNA Sciences and its competitors with MarketBeat's FREE daily newsletter.

APDN Company Calendar

Last Earnings
8/11/2022
Today
10/01/2022
Next Earnings (Estimated)
12/08/2022
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Miscellaneous business services
Sub-Industry
N/A
Current Symbol
NASDAQ:APDN
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+519.5%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-14,290,000.00
Pretax Margin
-68.79%

Debt

Sales & Book Value

Annual Sales
$9.03 million
Book Value
$1.48 per share

Miscellaneous

Free Float
11,220,000
Market Cap
$13.54 million
Optionable
Optionable
Beta
0.07

Key Executives

  • Dr. James A. Hayward Ph.D. (Age 68)
    Sc.D., Chairman, Pres & CEO
    Comp: $984.84k
  • Ms. Beth M. Jantzen CPA (Age 46)
    CPA, Chief Financial Officer
    Comp: $278.85k
  • Ms. Judith Murrah (Age 64)
    COO & Sec.
    Comp: $314.42k
  • Mr. Sanjay M. Hurry
    Exec. Director of Investor Relations & Corp. Communications
  • Mr. Clay Shorrock Esq. (Age 37)
    J.D., Chief Legal Officer & Exec. Director of Bus. Devel.
  • Mr. John Shearman
    Exec. Director of Marketing & Cannabis Bus.
  • Mr. Tony Benson
    Managing Director of EMEA
  • Ms. Janice Meraglia
    VP, Gov. & Military Programs
  • Ms. MeiLin Wan
    VP of Textile Sales
  • Dr. Stephen Hughes
    Director of DNA Programs













APDN Stock - Frequently Asked Questions

What is Applied DNA Sciences' stock price forecast for 2022?

0 Wall Street research analysts have issued twelve-month price targets for Applied DNA Sciences' stock. Their APDN share price forecasts range from $6.00 to $8.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 519.5% from the stock's current price.
View analysts price targets for APDN
or view top-rated stocks among Wall Street analysts.

How have APDN shares performed in 2022?

Applied DNA Sciences' stock was trading at $4.02 at the beginning of the year. Since then, APDN stock has decreased by 71.9% and is now trading at $1.13.
View the best growth stocks for 2022 here
.

When is Applied DNA Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 8th 2022.
View our APDN earnings forecast
.

How were Applied DNA Sciences' earnings last quarter?

Applied DNA Sciences, Inc. (NASDAQ:APDN) issued its earnings results on Thursday, August, 11th. The technology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.19. Applied DNA Sciences had a negative trailing twelve-month return on equity of 158.37% and a negative net margin of 68.79%.

What is James A. Hayward's approval rating as Applied DNA Sciences' CEO?

2 employees have rated Applied DNA Sciences Chief Executive Officer James A. Hayward on Glassdoor.com. James A. Hayward has an approval rating of 100% among the company's employees. This puts James A. Hayward in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Applied DNA Sciences to a friend.

What other stocks do shareholders of Applied DNA Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied DNA Sciences investors own include Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Ekso Bionics (EKSO), Micron Technology (MU), Arbutus Biopharma (ABUS), VBI Vaccines (VBIV), Gilead Sciences (GILD), Vaxart (VXRT), Sorrento Therapeutics (SRNE) and Intel (INTC).

What is Applied DNA Sciences' stock symbol?

Applied DNA Sciences trades on the NASDAQ under the ticker symbol "APDN."

How do I buy shares of Applied DNA Sciences?

Shares of APDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied DNA Sciences' stock price today?

One share of APDN stock can currently be purchased for approximately $1.13.

How much money does Applied DNA Sciences make?

Applied DNA Sciences (NASDAQ:APDN) has a market capitalization of $13.54 million and generates $9.03 million in revenue each year. The technology company earns $-14,290,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

How can I contact Applied DNA Sciences?

Applied DNA Sciences' mailing address is 50 HEALTH SCIENCES DRIVE, STONY BROOK NY, 11790. The official website for the company is www.adnas.com. The technology company can be reached via phone at (631) 240-8800, via email at investor@adnas.com, or via fax at 631-240-8900.

This page (NASDAQ:APDN) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.